Back to Search
Start Over
Epigenetic age acceleration among survivors of pediatric medulloblastoma and primitive neuroectodermal tumor.
- Source :
-
Pediatric hematology and oncology [Pediatr Hematol Oncol] 2023 May; Vol. 40 (4), pp. 407-411. Date of Electronic Publication: 2022 Jul 21. - Publication Year :
- 2023
-
Abstract
- Survivors of childhood central nervous system (CNS) tumors experience early-onset aging-related phenotypes. DNA methylation (DNAm) age is an emerging epigenetic biomarker of physiologic age and may be predictive of chronic health conditions in long-term survivors. This report describes the course of epigenetic age acceleration using post-diagnosis blood samples (median: 3.9 years post-diagnosis; range: 0.04-15.96) from 83 survivors of pediatric CNS tumors. Epigenetic age acceleration was detected in 72% of patients, with an average difference between chronologic and DNAm age of 2.58 years (95% CI: 1.75-3.41, p < 0.001). Time from diagnosis to sample collection correlated with the magnitude of epigenetic age acceleration.
- Subjects :
- Humans
Survivors
Epigenesis, Genetic
Medulloblastoma genetics
Medulloblastoma therapy
Medulloblastoma pathology
Neuroectodermal Tumors, Primitive genetics
Neuroectodermal Tumors, Primitive therapy
Neuroectodermal Tumors, Primitive pathology
Central Nervous System Neoplasms
Cerebellar Neoplasms genetics
Cerebellar Neoplasms therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1521-0669
- Volume :
- 40
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Pediatric hematology and oncology
- Publication Type :
- Academic Journal
- Accession number :
- 35862575
- Full Text :
- https://doi.org/10.1080/08880018.2022.2101722